2.83

4.39% -0.13

After Hours: 2.83

Galectin Therapeutics Inc (GALT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Galectin Therapeutics Inc stock is traded at $2.83, with a volume of 221.37K. It is down -4.39% in the last 24 hours and down -27.06% over the past month. Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Previous Close:

$2.96

Open:

$2.97

24h Volume:

221.37K

Relative Volume:

0.44

Market Cap:

$182.46M

Revenue:

Net Income/Loss:

$-45.08M

P/E Ratio:

-3.8767

EPS:

-0.73

Net Cash Flow:

$-33.68M

1W Performance:

-3.41%

1M Performance:

-27.06%

6M Performance:

-23.31%

1Y Performance:

+117.69%

1-Day Range:

$2.82

$2.985

1-Week Range:

$2.76

$3.30

52-Week Range:

$1.12

$7.13

Galectin Therapeutics Inc Stock (GALT) Company Profile

Name

Galectin Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (620)

Phone

678-620-3186

Address

4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA

Employee

Twitter

@galectingalt

Next Earnings Date

2025-03-31

Latest SEC Filings

GALT's Discussions on Twitter

Compare GALT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GALT Galectin Therapeutics Inc	2.83	190.84M	0	-45.08M	-33.68M	-0.73
VRTX Vertex Pharmaceuticals Inc	458.81	119.38B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	766.63	81.46B	14.34B	4.50B	3.88B	41.57
ARGX Argen X Se Adr	820.31	52.65B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	331.24	46.50B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	347.00	38.95B	4.98B	69.60M	525.67M	0.5198

Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-17-25	Resumed	H.C. Wainwright	Buy
Aug-13-20	Reiterated	H.C. Wainwright	Buy
Feb-13-19	Initiated	B. Riley FBR	Buy
Dec-07-17	Reiterated	H.C. Wainwright	Buy
Nov-28-17	Reiterated	H.C. Wainwright	Buy
Oct-19-17	Initiated	ROTH Capital	Buy
Mar-30-17	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-03-16	Downgrade	FBR & Co.	Outperform → Mkt Perform
Sep-29-16	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-28-16	Downgrade	ROTH Capital	Buy → Sell
Mar-28-16	Resumed	H.C. Wainwright	Buy
Sep-21-15	Initiated	H.C. Wainwright	Buy
Aug-01-14	Downgrade	Aegis Capital	Buy → Hold
Jul-30-14	Reiterated	MLV & Co	Buy
Jul-29-14	Reiterated	MLV & Co	Buy
Apr-02-14	Reiterated	MLV & Co	Buy
Feb-10-14	Reiterated	Aegis Capital	Buy
Jan-09-14	Reiterated	Aegis Capital	Buy
Dec-03-13	Initiated	MLV & Co	Buy
Aug-19-13	Reiterated	Aegis Capital	Buy

View All

Galectin Therapeutics Inc Stock (GALT) Latest News

Feb 01, 2026

Aug Chart Watch: Is Galectin Therapeutics Inc gaining market shareJuly 2025 Recap & Accurate Intraday Trade Tips - baoquankhu1.vn

Feb 01, 2026

Jan 30, 2026

Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap dropped US$39m last week; Individual investors bore the brunt - simplywall.st

Jan 30, 2026

Jan 27, 2026

What’s the outlook for Galectin Therapeutics Inc.’s sectorJuly 2025 Recap & Weekly Momentum Picks - Mfd.ru

Jan 27, 2026

Jan 26, 2026

Can Galectin Therapeutics Inc expand into new marketsJobs Report & Real-Time Volume Analysis - baoquankhu1.vn

Jan 26, 2026

Meme Stocks: Will Galectin Therapeutics Inc outperform its industry peersMarket Activity Report & Expert Approved Momentum Ideas - baoquankhu1.vn

Jan 26, 2026

Jan 23, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc.GALT - yourwyominglink.com

Jan 23, 2026

Jan 22, 2026

Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insiders - Yahoo Finance

Jan 22, 2026

Jan 20, 2026

Analysis Recap: Can Galectin Therapeutics Inc be the next market leaderTrade Entry Report & Smart Investment Allocation Insights - baoquankhu1.vn

Jan 20, 2026

Portfolio Update: Is DNAWS a potential multi baggerEarnings Beat & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn

Jan 20, 2026

Moving Averages: What is the Moat Score of WVVIPBuy Signal & Fast Entry and Exit Trade Plans - baoquankhu1.vn

Jan 20, 2026

Jan 19, 2026

Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Update - MarketBeat

Jan 19, 2026

Jan 15, 2026

Galectin Therapeutics Under Investigation, Stock Plummets 28.9% - Intellectia AI

Jan 15, 2026

Is Galectin Therapeutics Inc. gaining market shareJuly 2025 Analyst Calls & Safe Entry Point Identification - baoquankhu1.vn

Jan 15, 2026

Jan 14, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Galectin Therapeutics Inc. (GALT) And Encourages Shareholders to Reach Out - ACCESS Newswire

Jan 14, 2026

Insider Buy: Can BROG navigate macro headwindsWeekly Investment Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn

Jan 14, 2026

Jan 13, 2026

Growth Review: Is Galectin Therapeutics Inc stock affected by interest rate hikesQuarterly Earnings Report & Daily Growth Stock Investment Tips - Bộ Nội Vụ

Jan 13, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Galectin Therapeutics Inc. (GALT) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Jan 13, 2026